Results 131 to 140 of about 26,436 (212)

Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study

MedComm, Volume 7, Issue 10, October 2026.
In this study, perioperative camrelizumab plus apatinib demonstrated promising efficacy and safety in resectable hepatocellular carcinoma (HCC) patients at high risk of recurrence, achieving a major pathological response of 46.2%. The median disease‐free survival and progression‐free survival were 24.1 months and 18.3 months, respectively.
Yunlong Cui, Xu Bao, Ge Yu, Feng Fang, Qiang Li, Han Mu, Chen Liu, Qiang Wu, Wei Zhang, Huikai Li, Ping Chen, Xiaomeng Liu, Hongyuan Zhou, Tianqiang Song   +13 more
wiley   +1 more source

Efficacy and Safety of Co‐Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck‐001): A Phase II Trial

MedComm, Volume 7, Issue 10, October 2026.
Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen, Letao Lin, Shuanggang Chen, Chen Li, Ruizhi Tang, Lin Xie, Yujia Wang, Yunpeng Li, Hongliang Zou, Dandan Li, Xiaoshi Zhang, Weijun Fan   +11 more
wiley   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study

Cancer Medicine
Background and Aim Combining systemic chemotherapy with transarterial chemoembolization (TACE) has demonstrated improved outcomes, with promising results for the efficacy of lenvatinib pretreatment combined with TACE in single‐arm studies involving ...
Nobuhito Taniki, Keisuke Ojiro, Ryosuke Kasuga, Yukie Nakadai, Takaya Tabuchi, Po‐Sung Chu, Shingo Usui, Hitomi Hoshi, Fumihiko Kaneko, Akihiro Yamaguchi, Jun Koizumi, Hirotoshi Ebinuma, Masashi Tamura, Jitsuro Tsukada, Masanori Inoue, Seishi Nakatsuka, Yasushi Hasegawa, Yuta Abe, Minoru Kitago, Masahiro Jinzaki, Yuko Kitagawa, Takanori Kanai, Nobuhiro Nakamoto   +22 more
doaj   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma [PDF]

Yintao Wu,* Jianyong Zhu,* Hong Zhang, Nianxin Xia Senior Department of Hepato-Pancreato-Biliary Surgery, the First Medical Center of PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this ...
Zhu J, Zhang H, Xia N, Wu Y
core  

Iron Homeostasis and Liver Diseases

Journal of Cellular and Molecular Medicine, Volume 30, Issue 20, October 2026.
ABSTRACT Iron is an essential micronutrient whose ability to cycle between ferric (Fe3+) and ferrous (Fe2+) states makes it crucial for physiological processes, including oxygen transport, DNA synthesis, and oxidative phosphorylation. However, because both deficiency and excess can cause severe pathology, precise regulation is critical. The liver plays
Peng Yang, Zhitian Shi, Qin Huang, Zhihong Tu, Yue Sun, Lin Wang, Yonglong Wei   +6 more
wiley   +1 more source

Impact of PD‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims The optimal sequencing of programmed cell death protein 1 (PD‐1) inhibitors relative to locoregional therapy (LRT) in unresectable hepatocellular carcinoma (uHCC) remains undefined. This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or ...
Jian He, Jian Chen, Bohua Yu, Fuqun Wei, Weifu Liu, Peishu Huang, Songhui Wu, Xiang You, Zhisheng Chen, Ziqi Lin, Wuhua Guo, Shaowu Zhuang, Yiping Chen, Zhongwu Chen   +13 more
wiley   +1 more source

E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort. [PDF]

EClinicalMedicine
Lee JY, Hasegawa K, Kim BG, Berman B, Suzuki S, Corr B, Yunokawa M, Orr D, Yamamoto N, Soliman PT, Miller DS, Potdar AA, Sahara T, Kimura T, Dutta L, Wu J, McKenzie J, Kyi C.   +17 more
europepmc   +1 more source